TriCo Bancshares (TCBK)
NASDAQ: TCBK · Real-Time Price · USD
41.14
-0.12 (-0.29%)
At close: Aug 6, 2025, 4:00 PM
41.18
+0.04 (0.10%)
After-hours: Aug 6, 2025, 4:10 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Verve Therapeutics stock have a consensus rating of "Buy" and an average price target of $47.6, which forecasts a 15.70% increase in the stock price over the next year. The lowest target is $45 and the highest is $55.
Price Target: $47.60 (+15.70%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $52 → $55 | Buy | Maintains | $52 → $55 | +33.69% | Jul 28, 2025 |
| DA Davidson | DA Davidson | Hold Maintains $43 → $45 | Hold | Maintains | $43 → $45 | +9.38% | Jul 25, 2025 |
| Raymond James | Raymond James | Buy Reiterates $43 → $45 | Buy | Reiterates | $43 → $45 | +9.38% | Jul 25, 2025 |
| Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Maintains $48 → $46 | Hold | Maintains | $48 → $46 | +11.81% | Apr 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $47 | Buy | Reiterates | $47 | +14.24% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
425.98M
from 389.19M
Increased by 9.45%
Revenue Next Year
450.75M
from 425.98M
Increased by 5.81%
EPS This Year
3.37
from 3.46
Decreased by -2.48%
EPS Next Year
3.66
from 3.37
Increased by 8.49%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 440.8M | 481.9M | 468.8M |
| Avg | 426.0M | 450.8M | 455.4M |
| Low | 407.7M | 425.0M | 437.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.3% | 13.1% | 4.0% |
| Avg | 9.5% | 5.8% | 1.0% |
| Low | 4.8% | -0.2% | -2.9% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 3.56 | 3.93 |
| Avg | 3.37 | 3.66 |
| Low | 3.14 | 3.36 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | 2.9% | 16.6% |
| Avg | -2.5% | 8.5% |
| Low | -9.4% | -0.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.